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Methods: Expression levels of IGF-1R was evaluated by immuno-
precipitation using antibodies directed against IGF-1R, followed by 
SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) and Western 
blotting. 9 different cell lines, including both non-small cell and small 
cell lung cancer, were used in the analyses. Using the panel of IGF-1R 
expressing cell lines, we studied PPP-induced cell death by means of 
Fluorometric Microculture Cytotoxicity Assay (FMCA). We also com-
bined PPP treatment with a panel of various cytotoxic drugs in order to 
study potentially additive or synergistic effects. Gene expression proﬁl-
ing using the microarray technique on an Affymetrix platform was used 
to characterize the cell lines. Quantitative real-time RT-PCR was used 
to validate gene expression levels.
Results: The sensitivity to PPP differed between the various cell lines, 
yielding IC50-values ranging from below 1 to almost 100 μM. Within 
the tested concentration range PPP-effects were nicely dose-dependent, 
and the shapes of the concentration-response curves differed from those 
of PPT which were much shallower. However both drugs shared cell 
lines in which the highest and lowest activity was seen, and correlation 
analysis of endpoints yielded moderate correlation coefﬁcients. In ad-
dition, a panel of various cytotoxic drugs was tested in its effect on the 
lung cancer cells and a wide variation in sensitivity was noted between 
the cell lines. The gene expression proﬁles of the cells were examined 
using microarray technique and by statistical analyses, the proﬁles were 
evaluated for correlation with sensitivity to PPP. Further data on these 
analyses will be presented at the meeting. We also plan to study the 
effect of PPP on IGF-R signaling in the aformentioned cell lines from 
lung cancer and its importance to tumor biology, elucidating which 
signal proteins and pathways are affected by the treatment. 
Conclusions: IGF-1R constitutes a potential therapeutic target in lung 
cancer and since regulation of the IGF-1R signal pathway is disrupted 
in a variety of tumors, inhibitors may be useful in various diagnoses. 
The cyclolignan picropodophyllin (PPP) signiﬁcantly decreased cell 
viability in a concentration dependent manner in all lung cancer cell 
lines. PPP has been described as a speciﬁc inhibitor of IGF-1R, but 
in these experiments effects appear affected also by other, additional, 
mechanisms. 
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Background: Previous characterization of the novel melphalan 
containing pro-drugs J1 and J3 have revealed an increased cytotoxic-
ity in human tumour cells of various origins compared to the parental 
substance melphalan (Gullbo et al., 2003). J1 is now in a Phase I trial. 
In order to get increased knowledge about the cellular signalling trig-
gered by the melphalan-containing pro-drugs and trying to understand 
possible synergies with conventional chemotherapies, we have here 
compared the effects of J1, J3 and melphalan in NSCLC cell lines. 
Methods: NSCLC cells have been treated with either J1, J3 or melpha-
lan alone or in combination with standard chemotherapy. Cell viability 
upon treatments have been assessed using FMCA or MTT methods. 
Apoptotic signalling parameters (caspase-3 activation, mitochondrial 
depolarization, Bcl-2 family protein activation, Mitogen activated 
protein kinase (MAPK) activation) have been examined at various time 
points post treatment using a combination of ﬂow cytometry, western 
blotting and immunoﬂurescence microscopy analysis. 
Results and Conclusion: We report here that the melphalan pro-drug 
J1 causes a more rapid induction of apoptosis compared to melphalan 
in NSCLC cells. Moreover, our data show that J1-induced apoptotic 
signalling involves activation of Bak and Bax, depolarisation of mito-
chondria and activation of caspase-3. We report here that J1 causes an 
increased and more sustained activation of the MAPK JNK compared 
to melphalan. A role for JNK in J1-mediated cytotoxicity is shown by 
using pharmacological inhibitors. The importance of various cellular 
compartments for J1-mediated apoptotic signalling and the possible 
synergy with standard chemotherapy will also be discussed.
Reference:
 Gullbo J, Tullberg M, Vabeno J, Ehrsson H, Lewensohn R, Nygren P, Larsson R, Luth-
man K. (2003) Structure-activity relationship for alkylating dipeptide nitrogen mustard 
derivatives.Oncol Res. 14(3):113-32.
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Objective: To observe and compare the effect and side reaction of two 
kinds of combined chemotherapy in treating patients with advanced 
lung adenocarcinoma. One is Vinorelbine plus Oxaliplatin (NO) AND 
THE OTHER IS Vinorelbine plus Cisplatin (NP). 
Methods: 120 patients with advanced lung adenocarcinoma were 
divided into two groups. One group was treated with NO and the other 
was treated with NP,. Patients in two groups were well-matched in 
basic characteristics. All of them were treated by the two regimens 
responsively for 2 or 3 cycles. 
Results: The reponse rate was 43.3% in group NO and 45.0% in group 
NP. The median survival duration, one-year survival rate and three-year 
survival rate in NO group were eleven months, 38.3% and 8.3%; and 
in group NP they were ten months, 38.3% and 10.0%. There was no 
statistics difference in the curative effect of the two groups(P<0.05). 
Bone marrow inhibition was dose-limited toxicity of the two groups. 
The rates of III degree-IV degree neutropenia in group NO and NP 
were 22.2% and 21.6% (P<0.05). The rate of alimentary canal reaction 
in group NP was higher than the rate in group NO (P<0.05).The rate 
of renal disfunction in group NP was higher than the rate in group NO 
(P<0.05). The rate of neurotoxicity in group NO is higher the rate in 
group NP (P<0.05),but all patients, neurotoxicity can be renewed after 
chemotherapy. The rate of other unwanted reactions in two groups is 
similar. All side reactions can be endured. 
Conclusion: Both NO and NP are effective and safe in treating patients 
with advanced lung adenocarcinoma. The two regimens have the 
close curative effect. And the side reactions are similar. However, NO 
regimen has slighter toxicity in gastrointestin and renal function, so 
patients can endure better.
